Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide

por Bartlett, J B, Tozer, A, Stirling, D, Zeldis, J B
Publicado 2005

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)

por Liu, W M, Henry, J Y, Meyer, B, Bartlett, J B, Dalgleish, A G, Galustian, C
Publicado 2009

The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival

por Evans, C, Morrison, I, Heriot, A G, Bartlett, J B, Finlayson, C, Dalgleish, A G, Kumar, D
Publicado 2006

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced...

por Bartlett, J B, Michael, A, Clarke, I A, Dredge, K, Nicholson, S, Kristeleit, H, Polychronis, A, Pandha, H, Muller, G W, Stirling, D I, Zeldis, J, Dalgleish, A G
Publicado 2004